Articles tagged "Immunosuppression"

2017 American Transplant Congress
A Lower Mean Exposure to Tacrolimus, Not Intra-Patient Variability Is Associated with Chronic Active Antibody Mediated Rejection.
K. Sablik,¹ M. Clahsen–van Groningen,² T. Van Gelder,¹ M. Betjes.¹
¹Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands; ²Pathology, Erasmus MC, Rotterdam, Netherlands
Introduction. Chronic active antibody mediated rejection (caABMR) is one of the major causes of long-term kidney graft loss. It is hypothesized that frequent underexposure and…
2017 American Transplant Congress
Diabetes in Liver Transplantation: Evaluation of Management and Associated Clinical Outcomes.
A. Rogers,² N. Patel,² H. Meadows,² A. Mardis,² J. Fleming,² C. Perez,² I. Lee,² M. Sell,² B. O'Brien,² D. Taber,¹ K. Chavin,¹ D. Dubay,¹ C. Mardis,² N. Pilch.¹
¹Department of Surgry Division of Transplant, Medical University of South Carolina, Charleston, SC; ²Department of Pharmacy, Medical University of South Carolina, Charleston, SC
PurposeThere is limited data with diabetes management in liver transplant recipients and associated outcomes, this study aims to evaluate the long-term diabetes management in this…
2017 American Transplant Congress
Improvement of Cyclosporine A Dosing Strategy to Enhance Medication Adherence.
M. Barten,¹ E. Harmel,¹ M. Goldmann,¹ F. Wagner,¹ H. Reichenspurner,¹ M. Rybczynski.²
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
Background: It is known that the number of daily pills is crucial for medical adherence of patients after heart transplantation (HTx). For cyclosporine A (CsA)…
2017 American Transplant Congress
Immunosuppressive Role of Pancreas Derived Mesenchymal Stem Cells.
M. Kanak,¹ F. Kunnathodi,² M. Levy,^1,3 M. Lawrence,² B. Naziruddin.⁴
¹Transplant Surgery, Virginia Commonwealth University, Richmond, VA; ²Baylor Research Institute, Dallas, TX; ³Hume-Lee Transplant Center, VCU Health System, Richmond, VA; ⁴Simmons Transplant Institute, Baylor Scott and White Health, Dallas, TX
BackgroundThe Edmonton protocol revived islet transplantation therapy for Type-1 Diabetic patients. However, Long-term islet function still remains a challenge. Immunosuppression used after islet transplantation contributes…
2017 American Transplant Congress
Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).
H. Tedesco,¹ W. Irish,² K. Dharmesh,³ D. Patel,³ D. Cibrik.⁴
¹Hospital do Rim UNIFESP, Sao Paulo, Brazil; ²CTI Consulting, Raleigh; ³Novartis Pharmaceuticals Corporation, East Hanover; ⁴University of Michigan, Ann Arbor
MPA or mammalian target of rapamycin inhibitors (mTORi [EVR or SIR]) in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine) are used for maintenance…
2017 American Transplant Congress
Early Exposure of Everolimus with and without Calcineurin Inhibitors.
C. Felipe, A. Ferreira, T. Abait, A. Bessa, P. Ruppel, L. Hiramoto, M. Ivani, H. Tedesco, J. Medina- Pestana.
Nephrology Division, Hospital do Rim, UNIFESP, São Paulo, SP, Brazil
This study aimed to evaluate the effect of cyclosporine (CSA) or tacrolimus (TAC) on early exposure of everolimus (EVR).A cohort of 306 kidney transplant recipients…
2017 American Transplant Congress
Subclinical Histologic Findings Are Observed in 25% of Stable Adult Liver Transplant Recipients (ALTRs) Screened for Immunosuppression Withdrawal (ISW): OPTIMAL (NCT02533180).
S. Chandran,¹ M. Abecassis,² J. Levitsky,² S. Feng,³ A. Humar,⁴ J. Emond,⁵ G. Klintmalm,⁶ A. Demetris,⁴ K. Much,⁷ L. Sun,¹ A. Priore,⁸ D. Ikle,⁷ N. Bridges,⁸ M. DesMarais,¹ B. Burrell,⁹ J. Markmann.¹⁰
¹ITN, San Francisco; ²Northwestern, Chicago; ³UCSF, San Francisco; ⁴UPMC, Pittsburgh; ⁵Columbia, New York; ⁶Baylor, Dallas; ⁷Rho, Chapel Hill; ⁸NIAID/NIH, Bethesda; ⁹ITN, Bethesda; ¹⁰MGH, Boston
OPTIMAL is a 6-center ISW study in non-autoimmune, non-HCV ALTRs ≥3 yrs post-transplant (tx). Studies have shown a correlation between portal inflammation associated with tissue…
2017 American Transplant Congress
Protease Inhibitor-Based Regimens Are Associated with Inferior Outcomes in HIV-Infected Kidney Transplant Recipients.
B. Shelton,¹ D. Sawinski,² R. Reed,¹ P. MacLennan,¹ S. Mehta,¹ J. Locke.¹
¹University of Alabama at Birmingham, Birmingham; ²University of Pennsylvania, Philadelphia
Background: Excellent outcomes have been demonstrated among HIV-infected kidney transplant (KT) recipients when HIV infection is well-controlled. Protease inhibitors (PI) have significant drug-drug interactions with…
2017 American Transplant Congress
The Phenotypic and Functional Characteristics of a Novel CD11b⁺CD11c⁺F4/80⁺ Monocytic Myeloid-Derived Suppressor Cell Subset.
B. Jiang,^1,2 I. Aljabban,¹ C. Yang,¹ D. Ndishabandi,¹ R. White,¹ P. Russell,¹ J. Madsen,¹ R. Colvin,¹ A. Alessandrini.¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston; ²Dept. of Cardiac Surgery, Second Xiangya Hospital, Central South University, Changsha, China
Background: CD11b+Ly6G-Ly6Chigh monocytic myeloid-derived suppressor cells (M-MDSCs) in mice can promote the apoptosis of T cells and induce regulatory T cells. Novel CD11b+CD11c+F4/80+ cells were…
2017 American Transplant Congress
Efficacy and Safety of Everolimus with Reduced-Exposure Tacrolimus and Corticosteroid Withdrawal in De Novo Pediatric Renal Transplant Recipients: 12-Month Results from the CRADLE Study.
R. Ettenger,¹ B. Tönshoff,¹ H. Tedesco,¹ L. Dello Strologo,¹ S. Marks,¹ L. Pape,¹ E. Martzloff,² B. Rauer,² J. Ng,³ P. Lopez.²
¹A2314 Study Group, Los Angeles; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover
PURPOSE: We present 12-month (M) results from the CRADLE study (NCT01544491) that assessed efficacy and safety of everolimus (EVR) with reduced-exposure tacrolimus (rTAC) and early…